SecBot SecBot
SECBOTREPLAY Home › Report › LRMR

LRMR · Larimar Therapeutics is conducting a follow-on public offering of 20…

Larimar Therapeutics, Inc. · 8-K filed Feb 27, 2026 at 06:04 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Feb 27, 2026 at 06:04 ET

Larimar Therapeutics is conducting a follow-on public offering of 20 million shares at $5.00 per share, with underwriters exercising their full option to purchase an additional 3 million shares, resulting in expected net proceeds of approximately $107.6 million. The company plans to use the proceeds for general corporate purposes, including advancing its clinical programs and expanding operations.

  • Larimar Therapeutics is offering 20 million shares of common stock at $5.00 per share
  • Underwriters exercised their full option to purchase an additional 3 million shares
  • Expected net proceeds after underwriting discounts and commissions are approximately $107.6 million
  • J.P. Morgan Securities LLC and Guggenheim Securities, LLC are acting as joint bookrunning managers

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access